866-997-4948(US-Canada Toll Free)

Liver Cancer - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : Jun 2016

Category :

Cancer

No. of Pages : 1073 Pages

Liver Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Liver Cancer - Pipeline Review, H1 2016, provides an overview of the Liver Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Cancer
- The report reviews pipeline therapeutics for Liver Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Cancer therapeutics and enlists all their major and minor projects
- The report assesses Liver Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Liver Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Liver Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 9
Liver Cancer Overview 10
Therapeutics Development 11
Liver Cancer - Therapeutics under Development by Companies 13
Liver Cancer - Therapeutics under Investigation by Universities/Institutes 26
Liver Cancer - Pipeline Products Glance 28
Liver Cancer - Products under Development by Companies 31
Liver Cancer - Products under Investigation by Universities/Institutes 50
Liver Cancer - Companies Involved in Therapeutics Development 53
Liver Cancer - Therapeutics Assessment 223
Drug Profiles 250
Liver Cancer - Dormant Projects 999
Liver Cancer - Discontinued Products 1017
Liver Cancer - Product Development Milestones 1021
Appendix 1039

List of Tables
Number of Products under Development for Liver Cancer, H1 2016 44
Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016 45
Number of Products under Development by Companies, H1 2016 46
Number of Products under Development by Companies, H1 2016 (Contd..1) 47
Number of Products under Development by Companies, H1 2016 (Contd..2) 48
Number of Products under Development by Companies, H1 2016 (Contd..3) 49
Number of Products under Development by Companies, H1 2016 (Contd..4) 50
Number of Products under Development by Companies, H1 2016 (Contd..5) 51
Number of Products under Development by Companies, H1 2016 (Contd..6) 52
Number of Products under Development by Companies, H1 2016 (Contd..7) 53
Number of Products under Development by Companies, H1 2016 (Contd..8) 54
Number of Products under Development by Companies, H1 2016 (Contd..9) 55
Number of Products under Development by Companies, H1 2016 (Contd..10) 56
Number of Products under Development by Companies, H1 2016 (Contd..11) 57
Number of Products under Development by Companies, H1 2016 (Contd..12) 58
Number of Products under Investigation by Universities/Institutes, H1 2016 59
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 60
Comparative Analysis by Late Stage Development, H1 2016 61
Comparative Analysis by Clinical Stage Development, H1 2016 62
Comparative Analysis by Early Stage Development, H1 2016 63
Products under Development by Companies, H1 2016 64
Products under Development by Companies, H1 2016 (Contd..1) 65
Products under Development by Companies, H1 2016 (Contd..2) 66
Products under Development by Companies, H1 2016 (Contd..3) 67
Products under Development by Companies, H1 2016 (Contd..4) 68
Products under Development by Companies, H1 2016 (Contd..5) 69
Products under Development by Companies, H1 2016 (Contd..6) 70
Products under Development by Companies, H1 2016 (Contd..7) 71
Products under Development by Companies, H1 2016 (Contd..8) 72
Products under Development by Companies, H1 2016 (Contd..9) 73
Products under Development by Companies, H1 2016 (Contd..10) 74
Products under Development by Companies, H1 2016 (Contd..11) 75
Products under Development by Companies, H1 2016 (Contd..12) 76
Products under Development by Companies, H1 2016 (Contd..13) 77
Products under Development by Companies, H1 2016 (Contd..14) 78
Products under Development by Companies, H1 2016 (Contd..15) 79
Products under Development by Companies, H1 2016 (Contd..16) 80
Products under Development by Companies, H1 2016 (Contd..17) 81
Products under Development by Companies, H1 2016 (Contd..18) 82
Products under Investigation by Universities/Institutes, H1 2016 83
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 84
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 85
Liver Cancer - Pipeline by 4SC AG, H1 2016 86
Liver Cancer - Pipeline by AB Science SA, H1 2016 87
Liver Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016 88
Liver Cancer - Pipeline by ACROVIS Pharma AG, H1 2016 89
Liver Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016 90
Liver Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 91
Liver Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016 92
Liver Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 93
Liver Cancer - Pipeline by Alfact Innovation, H1 2016 94
Liver Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 95
Liver Cancer - Pipeline by American Gene Technologies International Inc., H1 2016 96
Liver Cancer - Pipeline by Amgen Inc., H1 2016 97
Liver Cancer - Pipeline by AndroScience Corporation, H1 2016 98
Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H1 2016 99
Liver Cancer - Pipeline by Arbutus Biopharma Corporation, H1 2016 100
Liver Cancer - Pipeline by ArQule, Inc., H1 2016 101
Liver Cancer - Pipeline by Array BioPharma Inc., H1 2016 102
Liver Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016 103
Liver Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 104
Liver Cancer - Pipeline by AstraZeneca Plc, H1 2016 105
Liver Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 106
Liver Cancer - Pipeline by Bayer AG, H1 2016 107
Liver Cancer - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016 108
Liver Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016 109
Liver Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 110
Liver Cancer - Pipeline by BioCancell Ltd, H1 2016 111
Liver Cancer - Pipeline by Biogazelle, H1 2016 112
Liver Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016 113
Liver Cancer - Pipeline by Bioneer Corporation, H1 2016 114
Liver Cancer - Pipeline by BioStar Pharmaceuticals, Inc., H1 2016 115
Liver Cancer - Pipeline by Blueprint Medicines Corporation, H1 2016 116
Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 117
Liver Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 118
Liver Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016 119
Liver Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016 120
Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2016 121
Liver Cancer - Pipeline by Celgene Corporation, H1 2016 122
Liver Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 123
Liver Cancer - Pipeline by Celprogen, Inc., H1 2016 124
Liver Cancer - Pipeline by Celsion Corporation, H1 2016 125
Liver Cancer - Pipeline by China Medical System Holdings Limited, H1 2016 126
Liver Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016 127
Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016 128
Liver Cancer - Pipeline by Chroma Therapeutics Limited, H1 2016 129
Liver Cancer - Pipeline by CohBar, Inc., H1 2016 130
Liver Cancer - Pipeline by CytRx Corporation, H1 2016 131
Liver Cancer - Pipeline by CZ BioMed Corp, H1 2016 132
Liver Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 133
Liver Cancer - Pipeline by Delcath Systems, Inc., H1 2016 134
Liver Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 135
Liver Cancer - Pipeline by Digna Biotech, S.L., H1 2016 136
Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016 137
Liver Cancer - Pipeline by Eisai Co., Ltd., H1 2016 138
Liver Cancer - Pipeline by Eli Lilly and Company, H1 2016 139
Liver Cancer - Pipeline by Endocyte, Inc., H1 2016 140
Liver Cancer - Pipeline by eTheRNA Immunotherapies NV, H1 2016 141
Liver Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016 142
Liver Cancer - Pipeline by Exelixis, Inc., H1 2016 143
Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 144
Liver Cancer - Pipeline by Genelux Corporation, H1 2016 145
Liver Cancer - Pipeline by Genoscience Pharma, H1 2016 146
Liver Cancer - Pipeline by Genosco, H1 2016 147
Liver Cancer - Pipeline by GenSpera, Inc., H1 2016 148
Liver Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 149
Liver Cancer - Pipeline by Golden Biotechnology Corp., H1 2016 150
Liver Cancer - Pipeline by Green Cross Cell Corporation, H1 2016 151
Liver Cancer - Pipeline by H3 Biomedicine Inc., H1 2016 152
Liver Cancer - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 153
Liver Cancer - Pipeline by HEC Pharm Co., Ltd., H1 2016 154
Liver Cancer - Pipeline by HitGen LTD, H1 2016 155
Liver Cancer - Pipeline by Horizon Pharma Plc, H1 2016 156
Liver Cancer - Pipeline by Huperion Sarl, H1 2016 157
Liver Cancer - Pipeline by Immunicum AB, H1 2016 158
Liver Cancer - Pipeline by Immunitor, Inc., H1 2016 159
Liver Cancer - Pipeline by Immunomedics, Inc., H1 2016 160
Liver Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016 161
Liver Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2016 162
Liver Cancer - Pipeline by In-Cell-Art S.A.S., H1 2016 163
Liver Cancer - Pipeline by Incanthera Ltd., H1 2016 164
Liver Cancer - Pipeline by Incuron, LLC, H1 2016 165
Liver Cancer - Pipeline by InteRNA Technologies B.V., H1 2016 166
Liver Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016 167
Liver Cancer - Pipeline by Jenrin Discovery, Inc., H1 2016 168
Liver Cancer - Pipeline by Johnson & Johnson, H1 2016 169
Liver Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2016 170
Liver Cancer - Pipeline by KAHR medical Ltd., H1 2016 171
Liver Cancer - Pipeline by Karcinolys SAS, H1 2016 172
Liver Cancer - Pipeline by Keystone Nano, Inc., H1 2016 173
Liver Cancer - Pipeline by Kite Pharma, Inc., H1 2016 174
Liver Cancer - Pipeline by Komipharm International Co., Ltd., H1 2016 175
Liver Cancer - Pipeline by Kowa Company, Ltd., H1 2016 176
Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016 177
Liver Cancer - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 178
Liver Cancer - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 179
Liver Cancer - Pipeline by Lytix Biopharma AS, H1 2016 180
Liver Cancer - Pipeline by MaxCyte, Inc., H1 2016 181
Liver Cancer - Pipeline by MedImmune, LLC, H1 2016 182
Liver Cancer - Pipeline by Medivation, Inc., H1 2016 183
Liver Cancer - Pipeline by Medivir AB, H1 2016 184
Liver Cancer - Pipeline by Merck & Co., Inc., H1 2016 185
Liver Cancer - Pipeline by Merck KGaA, H1 2016 186
Liver Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 187
Liver Cancer - Pipeline by Midatech Pharma Plc, H1 2016 188
Liver Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 189
Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2016 190
Liver Cancer - Pipeline by Molecular Partners AG, H1 2016 191
Liver Cancer - Pipeline by MolMed S.p.A., H1 2016 192
Liver Cancer - Pipeline by MultiCell Technologies, Inc., H1 2016 193
Liver Cancer - Pipeline by Nimbus Therapeutics, LLC, H1 2016 194
Liver Cancer - Pipeline by NormOxys, Inc., H1 2016 195
Liver Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016 196
Liver Cancer - Pipeline by Novartis AG, H1 2016 197
Liver Cancer - Pipeline by NovaTarg Therapeutics, Inc, H1 2016 198
Liver Cancer - Pipeline by Nymox Pharmaceutical Corporation, H1 2016 199
Liver Cancer - Pipeline by Omeros Corporation, H1 2016 200
Liver Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016 201
Liver Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016 202
Liver Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 203
Liver Cancer - Pipeline by OncoTherapy Science, Inc., H1 2016 204
Liver Cancer - Pipeline by Oneness Biotech Co., Ltd., H1 2016 205
Liver Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 206
Liver Cancer - Pipeline by Onxeo SA, H1 2016 207
Liver Cancer - Pipeline by OPKO Health, Inc., H1 2016 208
Liver Cancer - Pipeline by Oribase Pharma, H1 2016 209
Liver Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 210
Liver Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 211
Liver Cancer - Pipeline by Peptinov SAS, H1 2016 212
Liver Cancer - Pipeline by Pfizer Inc., H1 2016 213
Liver Cancer - Pipeline by Pharma Mar, S.A., H1 2016 214
Liver Cancer - Pipeline by PharmAbcine, Inc., H1 2016 215
Liver Cancer - Pipeline by PharmaEssentia Corporation, H1 2016 216
Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H1 2016 217
Liver Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 218
Liver Cancer - Pipeline by Progen Pharmaceuticals Limited, H1 2016 219
Liver Cancer - Pipeline by ProMetic Life Sciences Inc., H1 2016 220
Liver Cancer - Pipeline by Provecs Medical GmbH, H1 2016 221
Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 222
Liver Cancer - Pipeline by Quimatryx, S.L., H1 2016 223
Liver Cancer - Pipeline by Raptor Pharmaceutical Corp., H1 2016 224
Liver Cancer - Pipeline by RedHill Biopharma Ltd., H1 2016 225
Liver Cancer - Pipeline by Regen BioPharma, Inc., H1 2016 226
Liver Cancer - Pipeline by Regulus Therapeutics Inc., H1 2016 227
Liver Cancer - Pipeline by Rigontec GmbH, H1 2016 228
Liver Cancer - Pipeline by Saronic Biotechnology, Inc., H1 2016 229
Liver Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 230
Liver Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2016 231
Liver Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 232
Liver Cancer - Pipeline by Silence Therapeutics Plc, H1 2016 233
Liver Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016 234
Liver Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2016 235
Liver Cancer - Pipeline by Synovo GmbH, H1 2016 236
Liver Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 237
Liver Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016 238
Liver Cancer - Pipeline by Targetome, H1 2016 239
Liver Cancer - Pipeline by Therapure Biopharma Inc., H1 2016 240
Liver Cancer - Pipeline by Theravectys SA, H1 2016 241
Liver Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2016 242
Liver Cancer - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016 243
Liver Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 244
Liver Cancer - Pipeline by Transgene Biotek Limited, H1 2016 245
Liver Cancer - Pipeline by Tumorend, LLC, H1 2016 246
Liver Cancer - Pipeline by UbiVac, LLC, H1 2016 247
Liver Cancer - Pipeline by VasGene Therapeutics, Inc., H1 2016 248
Liver Cancer - Pipeline by Vaxon Biotech, H1 2016 249
Liver Cancer - Pipeline by Vect-Horus S.A.S., H1 2016 250
Liver Cancer - Pipeline by Verlyx Pharma Inc., H1 2016 251
Liver Cancer - Pipeline by VG Life Sciences, Inc., H1 2016 252
Liver Cancer - Pipeline by Vicus Therapeutics, LLC, H1 2016 253
Liver Cancer - Pipeline by Virttu Biologics Limited, H1 2016 254
Liver Cancer - Pipeline by Vyriad, H1 2016 255
Assessment by Monotherapy Products, H1 2016 256
Assessment by Combination Products, H1 2016 257
Number of Products by Stage and Target, H1 2016 259
Number of Products by Stage and Mechanism of Action, H1 2016 269
Number of Products by Stage and Route of Administration, H1 2016 280
Number of Products by Stage and Molecule Type, H1 2016 282
Liver Cancer - Dormant Projects, H1 2016 1032
Liver Cancer - Dormant Projects (Contd..1), H1 2016 1033
Liver Cancer - Dormant Projects (Contd..2), H1 2016 1034
Liver Cancer - Dormant Projects (Contd..3), H1 2016 1035
Liver Cancer - Dormant Projects (Contd..4), H1 2016 1036
Liver Cancer - Dormant Projects (Contd..5), H1 2016 1037
Liver Cancer - Dormant Projects (Contd..6), H1 2016 1038
Liver Cancer - Dormant Projects (Contd..7), H1 2016 1039
Liver Cancer - Dormant Projects (Contd..8), H1 2016 1040
Liver Cancer - Dormant Projects (Contd..9), H1 2016 1041
Liver Cancer - Dormant Projects (Contd..10), H1 2016 1042
Liver Cancer - Dormant Projects (Contd..11), H1 2016 1043
Liver Cancer - Dormant Projects (Contd..12), H1 2016 1044
Liver Cancer - Dormant Projects (Contd..13), H1 2016 1045
Liver Cancer - Dormant Projects (Contd..14), H1 2016 1046
Liver Cancer - Dormant Projects (Contd..15), H1 2016 1047
Liver Cancer - Dormant Projects (Contd..16), H1 2016 1048
Liver Cancer - Dormant Projects (Contd..17), H1 2016 1049
Liver Cancer - Discontinued Products, H1 2016 1050
Liver Cancer - Discontinued Products (Contd..1), H1 2016 1051
Liver Cancer - Discontinued Products (Contd..2), H1 2016 1052
Liver Cancer - Discontinued Products (Contd..3), H1 2016 1053

List of Figures
Number of Products under Development for Liver Cancer, H1 2016 44
Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016 45
Number of Products under Development by Companies, H1 2016 46
Number of Products under Investigation by Universities/Institutes, H1 2016 59
Comparative Analysis by Clinical Stage Development, H1 2016 62
Comparative Analysis by Early Stage Products, H1 2016 63
Assessment by Monotherapy Products, H1 2016 256
Assessment by Combination Products, H1 2016 257
Number of Products by Top 10 Targets, H1 2016 258
Number of Products by Stage and Top 10 Targets, H1 2016 258
Number of Products by Top 10 Mechanism of Actions, H1 2016 268
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 268
Number of Products by Top 10 Routes of Administration, H1 2016 279
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 279
Number of Products by Top 10 Molecule Types, H1 2016 281
Number of Products by Stage and Top 10 Molecule Types, H1 2016 281

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *